AaviGen GmbH

AaviGen GmbH, based in Heidelberg, is an innovative biotechnology company specializing in the development of precise gene therapy solutions. The focus is on the treatment of serious cardiovascular and cardiopulmonary diseases, in particular heart failure. AaviGen uses state-of-the-art platform technologies based on adeno-associated viruses (AAV), which enable the targeted and safe delivery of genetic material to diseased heart tissue. AaviGen's products and therapies focus on so-called “personalized gene therapies”, i.e. tailor-made gene therapies that are adapted to the specific needs of the respective patient. The aim is to sustainably improve the function of the weakened heart muscle and thus increase the quality of life and life expectancy of patients. An important part of their work is the development of vectors that are specially optimized for use in the cardiovascular field. This enables AaviGen to deliver drugs directly where they are needed - in the heart itself. Through intensive research, strategic partnerships and strong investor support, the company is driving forward the clinical development of its therapies. AaviGen is thus making a decisive contribution to the next generation of cardiac therapies and is positioning itself as a pioneer in the field of precise gene therapies for life-threatening cardiovascular diseases.